Neorecormon market forecast points to aging population and CKD demand
The Business Research Company says the global Neorecormon market is set to expand through 2035 as chronic kidney disease, chemotherapy-related anemia and an aging population drive demand for anemia therapies. North America held the largest share in 2025, while the report highlights rising healthcare spending and broader biologic access as additional growth factors.
Why it matters: - The Neorecormon market is tied to rising demand for anemia treatment in chronic kidney disease, oncology care and aging populations. - Growth in this market can affect access to erythropoiesis-stimulating therapies used to improve red blood cell production and patient quality of life. - The report frames Neorecormon as part of a broader shift toward biologic and long-term anemia management.
What happened: - The Business Research Company released its Neorecormon Market Report 2026, covering market size, trends and global forecasts through 2035. - The report says North America held the largest share of the global Neorecormon market in 2025. - The report includes regional coverage for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company made a free sample report available here. - The full report is available here.
The details: - Neorecormon is a biopharmaceutical treatment used to manage anemia caused by chronic kidney disease, chemotherapy or other conditions that reduce red blood cell production. - The therapy works as an erythropoietin-stimulating agent that encourages red blood cell generation and improves oxygen transport. - Historical market growth has been supported by more chronic kidney disease cases, more chemotherapy-related anemia, more dialysis facilities, clinical validation of recombinant erythropoietin and higher production of injectable biologics. - Future growth is expected to come from an aging population, stronger demand for long-term anemia therapies, broader access to biologic drugs, more focus on patient quality of life and wider use of biosimilar-compatible treatment protocols. - The report highlights greater use of erythropoiesis-stimulating agents, more anemia management among chronic kidney disease patients, rising adoption of biologic injectables, development of oncology-related anemia therapies and efforts to optimize hemoglobin levels. - The company also says the 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.
Between the lines: - Chronic kidney disease is a core demand driver because the condition reduces erythropoietin output and often leads to anemia. - The report cites UK data showing about 7.2 million people live with chronic kidney disease, or more than 10% of the population, with 3.25 million in advanced stages and 3.9 million in earlier stages. - The same source projects UK chronic kidney disease cases will rise to 7.61 million by 2033. - Rising healthcare spending can widen access to anemia therapies by improving insurance coverage, lowering out-of-pocket costs and funding anemia management programs. - The report cites UK healthcare expenditure of about $367 billion in 2023, up 5.6%, with long-term health and social care spending up 2.8% in real terms in 2022. - Demographic change is also a major factor, with the World Health Organization saying global life expectancy at birth reached 73.3 years in 2024 and the population aged 60 and above is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. - North America’s lead reflects advanced healthcare infrastructure, high chronic disease prevalence and higher healthcare spending.
What's next: - The report expects market growth to continue through 2035 as chronic disease rates and the elderly population rise. - Emerging regions may present new expansion opportunities as healthcare access improves. - The Business Research Company is also offering expert contact channels for follow-up on the report and related market analysis.
The bottom line: - Neorecormon demand is being pulled by chronic kidney disease, cancer-related anemia and an aging global population, with North America currently leading the market and broader biologic access expected to support future growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
News From Europe!
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.